Page 5 - Evaluate Safety News Today

/PRNewswire/ -- Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX: CSL), today announced that the companys manufacturing...

Data demonstrates potential for less frequent drug administrationTTI-0102 was well tolerated with no Serious Adverse Events reportedSupports EU and US regulatory submissions for human efficacy trials

A No-Objection Letter from Health Canada has been received, enabling the initiation of PNT2004’s Phase 1 therapeutic trial using 68Ga-PNT6555 for imaging and 177Lu-PNT6555 for therapy ... | May 16, 2022

SHP643-301 is A Multicenter, Open-Label Phase 3 Study to Evaluate Safety, PK, Pharmacodynamics, And Clinical Activity/Outcomes of TAKHZYRO for Prevention…

MILAN, Italy and SAN MATEO, Calif, Feb. 9, 2022 /PRNewswire/ -- Dompé farmaceutici S.p.A. and Dompé U.S. Inc. (collectively Dompé) announced today...

/PRNewswire/ -- Dompé farmaceutici S.p.A. and Dompé U.S. Inc. (collectively Dompé) announced today that the first patient has been enrolled in its Phase 3...

/PRNewswire/ -- Dompé farmaceutici S.p.A. and Dompé U.S. Inc. (collectively Dompé) announced today that the first patient has been enrolled in its Phase 3...

75 Patient Trial Underway to Evaluate Safety and Efficacy of the VenoValve as a Potential Treatment for Severe Deep Venous Chronic Venous Insufficiency (CVI)Severe CVI Impacts Approximately 2.4 million

Bavarian Nordic, BioCryst Pharmaceuticals, Integrated Biotherapeutics, Geovax, Batavia Biosciences, Globavir Biosciences, Collaboration Pharmaceuticals, Emergex Vaccines, ReiThera, Emergent BioSolutions, Mapp Biopharmaceuticals, Biofactura, Alkido Pharma, Flow Pharma, and others are developing potential drug candidates to improve the Marburg Virus Disease treatment scenario.  BioCryst is developing galidesivir in partnership with U.S. government agencies and other institutions. In September ...

Share this article Share this article FORT COLLINS, Colo., March 16, 2021 /PRNewswire/ -- Cytocom, Inc., a leading biopharmaceutical company creating next generation immune therapies, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for a Phase 2 clinical trial to evaluate the safety and efficacy of CYTO-205 as a treatment to slow or halt the progression of SARS-CoV-2, the virus that causes COVID-19. CYTO-205 is designe...